Prathibha Ranganathan, PhD

The cancer lab at CHG aims at understanding the basis of therapeutic resistance in cancer. The overall goal is to develop better strategies for improved patient outcome.  Cancer claims several lives every year, throughout the world. Despite several advances in the field of medicine, and continued efforts to develop better treatment options, the disease continues to pose several challenges to patients, clinicians and researchers alike. One of the major problems in the treatment of cancer is the resistance to therapy, whether it is targeted therapy or conventional chemotherapy. In many cases, precise diagnosis in terms of staging and subtype would be of immense importance in deciding the most effective therapeutic regimen. A comprehensive understanding of the molecular players would be key to developing novel therapeutic strategies, which give better patient outcome and also reduce adverse side effects. Our lab employs a combination of genomics, proteomics, bioinformatics and cell- based approaches to understand the tumor intrinsic and tumor extrinsic factors responsible for chemoresistance. The long-term goal is to be able to overcome the problem of chemoresistance.